SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming Deadlines - AGEN

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. and certain officers for alleged violations of federal securities laws during the Class Period from January 23, 2023, to July 17, 2024, seeking damages for misleading statements regarding the company's business and prospects [1][5]. Company Overview - Agenus is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab and botensilimab, which are in various stages of clinical trials for treating cancers such as cervical cancer, pancreatic cancer, and melanoma [3][4]. Legal Proceedings - The lawsuit, filed in the U.S. District Court for the District of Massachusetts, claims that the defendants made materially false and misleading statements about the effectiveness of their combination therapy, leading to an overstatement of clinical results and regulatory prospects [1][5]. - Shareholders who acquired Agenus securities during the Class Period have until November 5, 2024, to request appointment as Lead Plaintiff [2]. Recent Developments - On July 18, 2024, Agenus announced that the FDA advised against the submission of results for its immunotherapy combination for accelerated approval, leading to a significant stock price drop of $10.43 per share, or 58.83%, closing at $7.30 [6].